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Abstract: The current clinical model for genetic-testing is based on clinical-criteria/family-12 
history(FH) and a pre-defined mutation probability threshold.  It requires people to develop cancer 13 
before identifying unaffected individuals in the family to target prevention. This process is 14 
inefficient, resource intense and misses >50% of individuals/mutation carriers at risk. Population 15 
genetic-testing can overcome these limitations. It is technically feasible to test populations on a large 16 
scale; genetic-testing costs are falling and the acceptability/awareness is rising. 17 
MEDLINE/EMBASE/Pubmed/CINAHL/PsychINFO databases were searched using a free-text and 18 
MeSH terms; reference lists of publications retrieved screened; additionally web-based platforms, 19 
Google, and clinical-trial registries were searched. Quality of studies were evaluated using 20 
appropriate check-lists. A number of studies have evaluated population-based BRCA-testing in the 21 
Jewish-population. This has been found to be acceptable, feasible, clinically-effective, safe, 22 
associated with high satisfaction rates and extremely cost-effective. Data support change in 23 
guidelines to population-based BRCA-testing in the Jewish-population. Population panel-testing 24 
for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 gene mutations is the most cost-effective 25 
genetic-testing strategy in general-population women and can prevent thousands more 26 
breast/ovarian cancers than current clinical-criteria based approaches. A few ongoing studies are 27 
evaluating population-based genetic-testing for multiple cancer susceptibility genes in the general-28 
population but more implementation studies are needed. A future population-testing programme 29 
could also target other chronic diseases. 30 
 31 
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prevention, primary prevention 33 
 34 
1. Introduction 35 
A number of moderate to high penetrance cancer-susceptibility genes (CSG) with well-36 
established clinical utility have been identified over the last two decades, and testing for these is 37 
widely available in clinical practice. The prime, most well-known exemplars have been BRCA1 and 38 
BRCA2. BRCA1/BRCA2 carriers have a 17-44% risk of ovarian cancer (OC) and 69-72% risk of breast 39 
cancer (BC) till age 80 years.[1] The current model for genetic testing is still predominantly driven by 40 
family-history (FH) or clinical-criteria with testing undertaken in hospitals or specialist genetic clinics 41 
following informed pre-test counselling. These FH-based criteria have been used to calculate 42 
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 mutation probability with genetic testing offered over a pre-defined probability threshold. Clinical-43 
criteria have been loosened and this threshold for offering testing has fallen over the years (from an 44 
earlier high of 20%), with most countries/health systems now offering BRCA-testing at about a 10% 45 
BRCA-mutation probability. A number of different models, ranging from standardized criteria to 46 
complex mathematical (Empirical/Mendelian) methodologies have been used to calculate mutation 47 
probability and are used in clinical practice. Carrier identification has numerous potential clinical 48 
benefits, which have been the main drivers for genetic testing. Effective options for prevention and/or 49 
screening are well-established for these mutation-carriers in clinical practice. Unaffected BRCA-50 
mutation carriers can opt for: risk-reducing salpingo-oophorectomy (RRSO) to reduce their OC-51 
risk;[2] as well as MRI/mammography screening, and chemoprevention with selective estrogen-52 
receptor-modulators (SERM)[3] or risk-reducing mastectomy (RRM)[4] to reduce their BC-risk. 53 
Additionally, mutation identification enables informed reproductive and contraceptive choices 54 
which can impact risk, including timing of pill use, planning a family, as well as prenatal and pre-55 
implantation genetic-diagnosis (PGD)[5]. Cancer affected carriers can opt for novel drugs like PARP 56 
inhibitors which improve survival as well as gain access to newer precision medicine based targeted 57 
therapeutics through clinical trials.[6-8] 58 
Pre-test genetic-counselling is a fundamental element of international guidelines[9] for informed 59 
decision-making before genetic-testing. The model for counselling has evolved over the years, with 60 
the original Huntingdon Model involving a minimum of two 60 minute face-to-face pre-test 61 
counselling sessions[10] now archived as a fixture of the past. Telephone counselling, DVD-based 62 
and group based approaches have been found to be non-inferior to traditional 1:1 face-to-face 63 
counselling.[11-16] Over the years a wide variety of decision aids have been used as adjuncts to help 64 
informed decision making, such as booklets, pamphlets, audiotapes, computer-based programmes 65 
and web-based platforms. Another important recent development is the move away from traditional 66 
genetics clinics towards non-genetic clinicians undertaking routine pre-test counselling and testing 67 
at cancer diagnosis.[17]  68 
  69 
1.1. The need for change  70 
The current Clinical-criteria/FH-based system of genetic testing has many limitations. It is only 71 
moderately effective at identifying mutations and poor at ruling out the presence of one.[18] We[19] 72 
and others[20,21] have shown current testing-criteria miss >50% BRCA-carriers with a relevant cancer 73 
and an even higher proportion of unaffected carriers don’t fulfil current genetic-testing criteria. There 74 
are a number of reasons for this including paternal inheritance, poor communication within and 75 
between families, inability to access health records, population migration, smaller nuclear families, 76 
lack of awareness and pure chance. Besides number of carriers are missed because they will have a 77 
probability below the clinical testing threshold (their BRCA probability is not nil or 0). Additionally 78 
the current approach requires individuals to be aware of their FH of cancer, understand its 79 
importance, and contact their GP or relevant health professional. The health professional in turn 80 
needs to understand the importance of this history and needs to refer to an appropriate genetics 81 
centre/ clinician. This gate keeper approach requires people to jump through a number of hoops. Lack 82 
of public and health professional awareness and complexity/inefficiency of the current structure and 83 
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 testing pathway has led to restricted access and massive under-utilisation of genetic testing 84 
services.[22,23] Childers et al estimate that >70% BC and >80% OC patients eligible for genetic testing 85 
in the USA have never discussed this with a health professional.[22]  We recently analysed recent 86 
NHS genetic-laboratory BRCA-testing data from 1993-2014 across a 16 million Greater-London 87 
population and found that <3% of estimated BRCA-carriers had been identified to date.[23] Our 88 
forecasting models suggest detection-rates using the current system are inadequate to identify all 89 
BRCA-carriers in the population and even doubling them will need 165-years to identify the 90 
‘clinically detectable’ proportion of BRCA-carriers (~50% don’t fulfil clinical-testing criteria, 91 
remaining undetectable).[23] Given the small proportion of unaffected individuals getting cancer 92 
annually, even addition of unselected case series testing while useful in identifying the pool of 93 
individuals without strong FH of cancer, will require ~250 years to identify residual undetected BRCA 94 
carriers.[23] Why do we need to wait for decades for people to develop cancer before identifying 95 
mutation carriers and their at risk family members? With the effective options for cancer-risk 96 
management and prevention available for high-risk women, this raises serious questions about the 97 
adequacy of the current clinical-criteria/FH-based approach. A number of these limitations can be 98 
overcome by offering unrestricted/unselected population based testing. 99 
Next generation sequencing driven high throughput testing coupled with advances in 100 
bioinformatics has technologically enabled large scale population wide testing. Falling costs of testing 101 
and increasing population awareness of cancer genetics and its implications offers a timely 102 
opportunity to apply this knowledge and technology on a broad population-scale to provide an 103 
important impetus in healthcare towards disease prevention. We present a systematic review of the 104 
literature on population-based germline testing for BRCA gene mutations. We also explore future 105 
applicability and potential for this strategy across other CSGs/chronic disease. 106 
2. Methods 107 
 108 
2.1. Search strategy and selection criteria 109 
We systematically reviewed the current literature on population-based germline testing for 110 
BRCA-mutations using a comprehensive three step search strategy to identify relevant studies. First 111 
we searched the following five databases from inception to August 30 2018: MEDLINE, EMBASE, 112 
Pubmed, CINAHL, and PsychINFO. A common search strategy (Table-1) was developed for database 113 
searching using a combination of free text and controlled vocabulary (MeSH terms). Second, 114 
reference lists of publications retrieved in the first step were screened for relevant studies. Third, we 115 
searched additional web-based platforms including specialised journals, Google searches for grey 116 
literature, conference proceedings and clinical trial registries (ISRCTN registry/ClinicalTrials.gov 117 
registry).  118 
 119 
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 Objective 
 
To identify published literature on unselected population based germline 
testing  
Data sources A systematic review of articles with the use of MEDLINE (1946 to August 
2018), EMBASE (1974 to August 2018), Pubmed (1996 to August 2018), 
CINAHL (1937 to August 2018), PsychINFO (1806 to August 2018) 
Search strategy 49 searches were undertaken using the below PICO framework: 
Participants: unaffected men/women  
Intervention: unselected population genetic testing 
Comparison:  family history/clinical criteria genetic testing 
Outcomes: acceptability; detection rate; satisfaction; quality of life; cost-
effectiveness of unselected genetic testing 
1. (LOW RISK).ti,ab 
2. exp "LOW RISK"/ 
3. (POPULATION RISK).ti,ab 
4. exp "POPULATION RISK"/ 
5. 1 OR 2 OR 3 OR 4 
6. (CANCER).ti,ab 
7. exp "CANCER"/ 
8. 6 OR 7 
9. (POPULATION GENETIC TESTING).ti,ab 
10. exp "POPULATION GENETIC TESTING"/ 
11. (UNSELECTED GENETIC TESTING).ti,ab 
12. exp "UNSELECTED GENETIC TESTING"/ 
13. 9 OR 10 OR 11 OR 12 
14. 8 AND 13 
15. (FAMILY HISTORY).ti,ab 
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 16. exp  "FAMILY HISTORY "/ 
17. 15 OR 16 
18. (GENETIC TESTING).ti,ab 
19. exp "GENETIC TESTING"/ 
20. 18 OR 19 
21. 8 AND 17 AND 20 
22. (BRCA).ti,ab 
23. exp "BRCA"/ 
24. (BRCA AND "1 OR 2").ti,ab 
25. exp "BRCA AND 1 OR 2"/ 
26. (BRCA AND 1).ti,ab 
27. exp " BRCA AND 1"/ 
28. (BRCA AND 2).ti,ab 
29. exp "BRCA AND 2"/ 
30. 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 
31. 8 AND 30 
32. 14 OR 21 OR 31 
33. (ACCEPTABILITY).ti,ab 
34. exp "ACCEPTABILITY"/ 
35. 33 OR 34 
36. (DETECTION RATE).ti,ab 
37. exp "DETECTION RATE"/ 
38. 36 OR 37 
39. (SATISFACTION).ti,ab 
40. exp "SATISFACTION"/ 
41. 39 OR 40 
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 Table-1. Search strategy for literature search 120 
Predefined inclusion criteria were unselected, unaffected individuals at population level risk 121 
undergoing genetic-testing for cancer predisposing genes. Outcomes investigated in relation to 122 
population genetic testing were: 1) acceptability, 2) testing uptake, 3) mutation detection rate, 4) 123 
satisfaction, 5) quality-of-life, 6) psychological health, 7) genetic counselling, 8) knowledge, 9) risk 124 
perception, 10) cost-effectiveness. 125 
 126 
2.2. Data extraction and quality assessment 127 
Data were extracted using a standardised, predesigned data extraction sheet in Microsoft Excel 128 
2013. Four main categories of data were extracted: methodological characteristics of each study, study 129 
population, details of interventions and reported outcome measures pertaining to population genetic 130 
42. (QUALITY OF LIFE).ti,ab 
43. exp "QUALITY OF LIFE"/ 
44. 42 OR 43 
45. (COST EFFECTIVE).ti,ab 
46. exp "COST EFFECTIVE"/ 
47. 45 OR 46 
48. 35 OR 38 OR 41 OR 44 OR 47 
49. 5 AND 32 AND 48 
Eligibility criteria Unselected, unaffected individuals at population level risk undergoing genetic 
testing for cancer predisposing genes; full text articles in English language. 
Data extraction Citations, abstracts extracted and reviewed by FG. Relevant papers reviewed 
by authors FG and RM.  
Conclusion Population genetic testing can overcome the limitations of family 
history/clinical criteria genetic testing. The technology to test populations on a 
large scale is available and the cost of testing is falling. Population based BRCA 
testing has been evaluated in the Jewish population and found to be 
acceptable, clinically effective, safe and cost-saving. However, these data 
cannot be ‘directly’ extrapolated to the non-Jewish general population. While 
recent data suggest genetic testing for breast/ovarian cancer gene mutations 
could be cost-effective in general population women too, additional research 
including implementation studies in the general population are needed to 
address various knowledge gaps before that step can be considered. 
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 testing. The quality of the studies was assessed depending on study design, using the following 131 
checklists: Quality of Health Economic Studies (QHES) checklist,[24] Critical Appraisal Skills 132 
Programme (CASP) qualitative research checklist, [25]Jadad scale for reporting randomized 133 
controlled trials[26] and Methodological Index for Non-Randomized Studies (MINORS) 134 
checklist.[27] 135 
2.3. Data analysis 136 
We tabulated characteristics and reported outcome measures of all studies for qualitative 137 
synthesis. 138 
3. Results 139 
Figure-1 provides the flow chart outlining the search outcomes and study selection process. 140 
Searches of electronic databases and reference lists generated 323 references. On evaluation of all 141 
titles and abstracts, 32/323 articles were potentially eligible for detailed assessment. 26/32 met our 142 
inclusion criteria for qualitative synthesis.[19-21,28-50] Relevant studies on population testing and 143 
design/outcomes/quality are summarised in Table-2. Table-3 encapsulates the main 144 
findings/conclusion from each study. 145 
 146 
3.1. The Jewish BRCA Model 147 
The majority of the evidence base for population-based testing currently comes from BRCA 148 
founder mutation testing (as the genetic disease model) in the Jewish population (population model). 149 
Six studies describe attitudes, interest, intention, barriers, and facilitators of BRCA testing in the AJ 150 
population (Table-2, Table-3).[29,30,45-47,51] Four main studies have evaluated the impact of 151 
unselected population-based BRCA-testing in the Jewish population: Two Israeli cohort studies (8195 152 
men & 1771 women/men)[20,52]; One Canadian cohort study (2080 women)[21]; and one UK 153 
randomised controlled trial (RCT) (1034 women and men)[19]. Details of these studies and published 154 
outputs are described in Table-2 and Table-3. These studies demonstrate that population-based 155 
BRCA-testing in the Jewish population is feasible, acceptable, safe, can be undertaken in a community 156 
setting, and identifies >50% additional BRCA-carriers who would have been missed by traditional 157 
clinical-criteria. RCT data show no significant difference in psychological well-being and quality-of-158 
life outcomes between population-based and FH/Clinical-criteria based BRCA-testing 159 
approaches.[19] Overall anxiety and uncertainty with BRCA-testing were found to decrease with 160 
time.[19] Israeli and Canadian cohort data show increased anxiety and distress in identified mutation 161 
carriers at 6 months/1 year.[52,53]  However, overall satisfaction rates are high for all participants 162 
(>91%) and similar to non-carriers.[52] Hence, outcomes seen with population-based testing appear 163 
to be similar to those reported from high-risk clinics.[54]  164 
Both Israeli and UK data suggest testing uptake and satisfaction rates are higher for testing 165 
undertaken through self-referral in ambulatory or community centres compared to hospital 166 
ascertainment.[19,52] Qualitative data re-confirm overall satisfaction with population-based BRCA-167 
testing reported with quantitative analyses, with 81% carriers and 90% non-carriers interviewed 168 
expressing unequivocal positive attitudes towards the BRCA-testing experience.[51] Barriers and 169 
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 facilitators reported with population-testing are similar to those found in high risk clinics. Other 170 
emergent themes reported include the need for incorporating testing into routine practice through 171 
primary care and via non-genetic clinicians as well as preservation of autonomy in decision 172 
making.[51] Familial communication following testing has been found to be associated with overall 173 
satisfaction with the process and FH of cancer. Initial cascade testing rates are higher in first-degree 174 
than second-degree relatives.[33] 175 
 176 
  177 
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  178 
 179 
180 
323 records retrieved for review: 
MEDLINE=121, EMBASE=7, Pubmed =148, 
CINAHL=39, PsychINFO=8). 
282 identified for title and abstract 
250 excluded for failure to meet 
eligibility criteria: 
200 = outcomes related to family history 
based clinical criteria for genetic testing  
50 = literature reviews, conference 
32 identified for full text screening 
26 included for qualitative synthesis 
(Table-2 and Table-3) 
49 duplicates excluded 
26 identified as relevant for data extraction 
8 identified through secondary 
6 full-text articles excluded: 
2 = review articles 
4 = outcomes related to family history 
Figure-1. Flowchart of study selection 
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Publication/register
ed study 
Country Sample size 
(n) 
Study design Population Intervention Outcomes  Follow up  Quality of study 
methodology 
Brown, 1995[28] US N/A Cost-
effectiveness 
analysis 
General population  PGT for MSH2/MLH1  Cost per life year gained N/A 31/100£ 
Cousens, 2017[29]  Australia 370 Prospective, 
survey 
AJ women Survey on BRCA1/BRCA2 PGT Attitudes; acceptability; interest None 13/16# 
Gabai-Kapara, 
2014[20] 
Israel 8195 (& 694 
relatives of 
carriers) 
Prospective 
cohort 
AJ men/women PGT for AJ BRCA1/BRCA2 founder 
mutations 
Risk of BC/OC in female carriers 
ascertained through an unaffected male 
index subject 
Not 
reported 
12/16# 
Lehmann, 2002[30] US 200 Prospective, 
survey 
AJ women Telephone survey  on 
BRCA1/BRCA2 PGT 
Attitudes; acceptability None 12/16# 
Lieberman, 
2017[31] 
Israel 36 Qualitative AJ men/women Semi structured interviews in 
individuals undergoing  PGT for AJ 
BRCA1/BRCA2 founder mutations 
Motivators/barriers to testing; satisfaction 18 months Good~ 
Lieberman, 
2017[32] 
Israel 1,771 Prospective 
cohort 
AJ men/women PGT for AJ BRCA1/BRCA2 founder 
mutations 
Uptake; post-test counselling compliance; 
satisfaction; anxiety; distress; increase in 
knowledge 
6 months 12/16# 
Lieberman, 
2018[33] 
Israel 1,771 Prospective, 
cohort 
AJ men/women PGT for AJ BRCA1/BRCA2 founder 
mutations 
Familial communication; cascade testing 2 years 12/16# 
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 Manchanda, 
2015[19] 
(ISRCTN73338115) 
UK 1,034 Randomised 
controlled trial 
AJ men/women PGT versus FH based testing  of  
AJ BRCA1/BRCA2 founder 
mutations  
Acceptability; psychological impact; QoL 3 months 5/5* 
Manchanda, 
2015[34] 
(ISRCTN73338115) 
UK N/A Cost-utility 
analysis 
AJ women 
 
PGT versus FH based testing for AJ 
BRCA1/BRCA2 founder mutations  
Incremental cost effectiveness 
ratio per quality adjusted life year 
N/A 96/100£ 
Manchanda, 
2016[35] 
(ISRCTN73338115) 
UK 936 Cluster 
randomised 
non-inferiority 
trial 
AJ men/women DVD assisted versus face-to-face 
pre-test counselling in individuals 
undergoing PGT of  AJ 
BRCA1/BRCA2 founder mutations 
Uptake; cancer risk perception; increase 
in knowledge; counselling time; 
satisfaction 
N/A 4/5* 
Manchanda, 
2017[36] 
UK, US N/A Cost-utility 
analysis 
AJ women 
 
PGT versus FH based testing for AJ 
BRCA1/BRCA2 founder mutations 
with differing AJ ancestry  
Incremental cost effectiveness 
ratio per quality adjusted life year 
N/A 90/100£ 
Manchanda, 
2018[37] 
UK, US N/A Cost-utility 
analysis 
General population women PGT versus FH based testing of   
BRCA1/BRCA2/ 
RAD51C/RAD51D/BRIP1/PALB2 
mutations 
Incremental cost effectiveness 
ratio per quality adjusted life year 
N/A 96/100£ 
Meisel, 2016[38] UK 829 Prospective, 
cohort 
General population women Survey  Interest; attitudes None 12/16# 
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 Meisel, 2017[39] UK 1031 Randomised  
experimental 
survey  
General population women Brief information versus lengthier 
information to inform decision 
making about participating in a 
study (PROMISE study) on 
PGT for OC  
Knowledge; intention; attitudes towards 
taking part in the PROMISE study 
None 3/5* 
Meisel, 2017[40] UK 837 Cross-sectional 
survey  
General population women Survey  on BRCA1/BRCA2 PGT Anticipated health behaviour change; 
perceived control to disclosure of OC/BC 
risk 
None 11/16# 
Metcalfe, 2010[21] Canada 2080 Prospective, 
cohort 
AJ/SJ women PGT for Jewish BRCA1/BRCA2 
founder mutations 
Mutation prevalence None 14/16# 
Metcalfe, 2010[41] Canada 2080 Prospective, 
cohort 
AJ/SJ women PGT for Jewish BRCA1/BRCA2 
founder mutations 
Satisfaction; cancer related distress; cancer 
risk perception 
1 year 14/16# 
Metcalfe, 2012[42] Canada 2080 Prospective, 
cohort 
AJ/SJ women PGT for Jewish BRCA1/BRCA2 
founder mutations 
Cancer related distress; uptake of cancer 
risk 
reduction options 
2 years 14/16# 
Patel, 2018[43] UK, US N/A Cost-utility 
analysis 
SJ women PGT  versus FH based testing for SJ 
BRCA1 founder mutations 
Incremental cost effectiveness 
ratio per quality adjusted life year 
N/A 90/100£ 
Rubinstein, 
2009[44] 
US N/A Cost-utility 
analysis 
AJ women PGT for  AJ BRCA1/BRCA2 founder 
mutations versus ‘no’ genetic testing 
Incremental cost effectiveness N/A 71/100£ 
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  ratio per quality adjusted life year 
Schwartz, 2001[45] US 391 Randomised 
controlled trial 
AJ women PGT for BRCA1/BRCA2 educational 
material versus 
general BC education control 
material 
Knowledge; perception of 
risks and limitations; interest 
1 month 3/5* 
Shkedi-Rafid, 
2012[46]  
Israel 14 Qualitative Unaffected BRCA1/BRCA2 
AJ female carriers 
ascertained following a 
positive test result in a male 
family member who 
underwent PGT 
Semi structured in-depth interviews 
on  PGT for  AJ BRCA1/BRCA2 
founder mutations 
Emotional implications;  
motivations;  
consequences; 
attitudes 
None Good~ 
Tang, 2017[47]  US 243 Cross-sectional 
survey 
Orthodox AJ women Survey on  PGT for BRCA1/BRCA2 Knowledge; perceived BC risk/worry; 
religious/cultural factors affecting decision 
making 
None 13/16# 
Warner, 2005[48] Australia 300 Prospective, 
cohort 
AJ men/women PGT for APC I1307K mutation, but 
non-disclosure of results 
Acceptability; facilitators and barriers to 
testing 
None 10/16# 
PROMISE Feasibility 
Study[49] 
(ISRCTN54246466) 
UK 100 Prospective, 
cohort 
General population women PGT for 
BRCA1/BRCA2/RAD51C/RAD51D/B
RIP1 and subsequent risk stratified 
screening and prevention 
Acceptability; risk perception; cancer 
worry; QoL; stratification of OC risk; 
uptake of risk management options; 
satisfaction/regret; follow up completion 
rate; telephone helpline use; decision aid 
use 
6 months N/A 
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 Table-2. Publications and registered studies reporting population genetic testing outcomes  181 
PGT – population genetic testing; FH – family history; AJ – Ashkenazi Jewish; SJ – Sephardi Jewish; QoL – quality of life; BC – breast cancer; OC – ovarian cancer; 182 
PROMISE - Predicting risk of ovarian malignancy improved screening and early detection feasibility study; ICER – incremental cost-effective ratio; QALY – quality 183 
adjusted life year 184 
£Quality of study assessed using Quality of Health Economic Studies (QHES) checklist  185 
˜Quality of study assessed using the Critical Appraisal Skills Programme (CASP) qualitative research checklist 186 
*Quality of study assessed using the Jadad scale for reporting randomized controlled trials 187 
#Quality of study assessed using the Methodological Index for Non-Randomized Studies (MINORS) checklist 188 
 189 
The Screen 
Project[50] 
Canada 10,000 Prospective, 
cohort 
General population 
men/women 
PGT for BRCA1/BRCA2 Satisfaction; cancer worry Not 
reported 
N/A 
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Publication/registered 
study 
Findings 
Brown, 1995[28] Exploratory analysis for cost effectiveness of PGT for MMR gene mutations MLH1/MSH2 compared to FH testing. PGT may be cost-effective if the base case analysis assumes 
a restrictive set of assumptions most favourable to the outcome with respect to prevalence, costs, clinical efficacy of screening and preventive interventions.  
Cousens, 2017[29]  96.8% support a Jewish BRCA1/BRCA2 testing program; 65.6 % interested in undergoing PGT. Interest in population based BRCA testing was higher in women <50 years 
than women >50 years.  
Gabai-Kapara, 2014[20] For female relatives with BRCA1/BRCA2 mutations identified through unaffected AJ male relatives, cumulative risk of developing BC/OC by age 60 and 80 respectively were 
0.60/0.83 for BRCA1; 0.33/0.76 for BRCA2 carriers. 2.17% AJ carry a BRCA1/BRCA2 mutation. 
Lehmann, 2002[30] 40% AJ women interested in PGT for BRCA1/BRCA2, 40% not interested, and 20% uncertain. Increased interest associated with desire to obtain information on children’s risk 
and valuing information for its own sake. 17% expressed concern or discomfort about Jews being offered BRCA1/2 testing. Increased concern about genetic discrimination 
associated with highly educated women. 
Lieberman, 2017[31] Motivators for BRCA testing: knowledge of BRCA status to enable cancer risk reduction; health-empowerment. Barriers: lack of physician awareness/support. Routinization 
of testing can overcome medical and social barriers. Importance of maintaining/safeguarding autonomy of choice and providing adequate post-test services was highlighted. 
Lieberman, 2017[32] BRCA testing uptake 67%. Post-test counselling compliance 100% for carriers; 89% for non-carriers with FH. All groups had high satisfaction (>90%). At 6 months, carriers 
had significantly increased distress/anxiety; greater knowledge; similar satisfaction to non-carriers. 90% recommended PGT for BRCA in the AJ community. Proactive 
recruitment through a clinical service captured older women more unselected for FH compared to self-referral based recruitment. 
Lieberman, 2018[33] 97% carriers informed at least one relative. FH and higher Satisfaction With Health Decision scores predicted results communication. FDRs had a higher rate of 
cascade/predictive testing than SDRs. Female relatives had a higher level of cascade testing than male relatives. 
Manchanda, 2015[19] 
(ISRCTN73338115) 
Compared with FH based testing, PGT for BRCA1/BRCA2 AJ founder mutations, does not adversely affect short-term psychological/QoL outcomes and may detect 56% 
additional BRCA carriers. 56% of carriers do not fulfil clinical criteria for genetic testing, and the BRCA1/2 prevalence is 2.45%. 
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 Manchanda, 2015[34] 
(ISRCTN73338115) 
PGT for AJ BRCA1/BRCA2 founder mutations is cost saving with a baseline discounted ICER of -£2079/QALY. PGT lowered OC/BC incidence by 0.34% and 0.62% respectively. 
Assuming 71% testing uptake, this leads to 276 fewer OC and 508 fewer BC cases. Overall, reduction in treatment costs leads to a discounted cost savings of £3.7 million in 
the UK population. 
Manchanda, 2016[35] 
(ISRCTN73338115) 
DVD assisted counselling for PGT is non-inferior to face-to-face counselling for increase in knowledge; counselling satisfaction; risk perception and is equivalent for uptake. 
98% found DVD length/information satisfactory. 85–89% felt it improved understanding of risks/benefits/implications/purpose of PGT. 95% would recommend it to others. 
Manchanda, 2017[36] PGT for BRCA mutations is cost-saving in AJ with 2-4 grandparents (22-33 days life gained) in the UK and 1-4 grandparents (12-26 days life-gained) in the US. It is extremely 
cost-effective in women in the UK with 1 AJ grandparent with ICER=£863/QALY; 15 days life gained. PGT remains cost-effective in the absence of reduction in BC risk from 
RRSO; at lower RRM (13%) or RRSO (20%) rates. 
Manchanda, 2018[37] Population panel genetic testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is the most cost-effective genetic testing strategy compared with current 
policy: ICER=£21,599.96/QALY or $54,769.78/QALY (9.34 or 7.57 days’ life-expectancy gained). PGT for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 
1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million. 
Meisel, 2016[38] 85% reported they would ‘probably’ or ‘definitely’ take up PGT for OC which increased to 88% if test also informed BC risk. 92% anticipated they would ‘probably’ or 
‘definitely’ participate in risk-stratified OC screening. University level education is associated with lower anticipated uptake of PGT. 
Meisel, 2017[39] No significant differences between participants receiving brief versus lengthier information to inform decision making in terms of OC knowledge/intention to participate in 
OC screening following PGT. 74% reported they would participate in OC screening based on PGT assessment. 
Meisel, 2017[40] UK women anticipate that they would engage in positive health behaviour changes in response to BCOC risk disclosure.72% reported ‘I would try harder to have a healthy 
lifestyle’; 55% felt ‘it would give me more control over my life’. Associations were independent of demographic factors or perceived risk of OC/BC.  
Metcalfe, 2010[21] Overall BRCA1/BRCA2 prevalence in unselected Jewish women undergoing PGT was 1.1% (0.5% for BRCA1 and 0.6% for BRCA2). Only 45% met clinical testing criteria. 
Metcalfe, 2010[41] In Jewish BRCA carriers, mean BC risk perception increased significantly from 41.1% to 59.6% after receiving a positive result. Among non-carriers, BC risk perception 
decreased non-significantly, from 35.8% to 33.5%. Cancer related distress increased significantly for carriers, but not in non-carriers. 92.8% satisfied with PGT. 
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 Metcalfe, 2012[42] Within 2 years of receiving a positive Jewish BRCA founder mutation result, 11.1% had RRM; 89.5% RRSO. Mean BC risk estimated to be 37.2% at time of testing versus 20.9% 
at 2 years post-testing. Distress decreased between 1 and 2 years for women with RRM/RRSO and for women with only RRSO but not for those with no surgery.  
Patel, 2018[43] PGT is cost-effective for SJ BRCA1 founder mutation. It results in 12 months (QALY=1.00) gain in life expectancy. Baseline discounted ICER for UK PGT = £67.04/QALY; US 
population= $308.42/QALY. PGT remains cost effective in UK/US, even if premenopausal RRSO doesn’t reduce BC risk or if HRT compliance is nil. 
Rubinstein, 2009[44] Compared to a no testing policy, PGT for AJ BRCA1/BRCA2 founder mutations is cost-effective and would result in 2,811 fewer cases of OC, with a life expectancy gain of 
1.83 QALYs among carriers. At a cost of $460 for founder mutation testing, the cost of the program is $8,300/QALY. 
Schwartz, 2001[45] Compared to the BC education control material, the PGT education material led to increased knowledge; increased perception of the risks/limitations of testing; and a 
decreased interest in obtaining a BRCA1/BRCA2 test. 
Shkedi-Rafid, 2012[46]  Having no FH of cancer was a source of optimism but also confusion; engaging in intensified medical surveillance and undergoing preventive procedures was perceived as 
health promoting but also induced a sense of physical/psychological vulnerability; overall support for population BRCA testing in the AJ community, with some reservations. 
Tang, 2017[47]  49% had adequate genetic testing knowledge; 46% had accurate BC risk perceptions. 20% reported they probably/definitely will get tested; 28% probably/definitely will not 
get tested; 46% had not thought about BRCA testing. Adequate genetic testing knowledge, higher BC risk, and overestimation of risk is associated with PGT intention. 
Cancer prevention and effect on children were the most important factors affecting testing intention. 
Warner, 2005[48] Following pre-test counselling 94% acceptability for PGT for colorectal cancer, but participants were not disclosed results. Facilitators: desire for information for their families; 
to decrease personal cancer risk. Barriers: insurance discrimination; test accuracy; confidentiality. 
PROMISE Feasibility 
Study[49] 
(ISRCTN54246466) 
Not reported. Study closed to recruitment and in follow up phase. 
The Screen Project[50] Not reported. Study actively recruiting. 
Table-3. Findings of publications and registered studies reporting population genetic testing outcomes  190 
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 PGT – population genetic testing; FH – family history; AJ – Ashkenazi Jewish; QoL – quality of life; BC – breast cancer; OC – ovarian cancer; FDR – first degree 191 
relative; SDR – second degree relative; ICER – incremental cost-effective ratio; QALY – quality adjusted life year 192 
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For large-scale, population-based genetic-testing to become feasible/practical it is necessary to 193 
move away from the cost and time intensive ‘traditional face-to-face’ genetic-counselling[55] 194 
approach. A UK non-inferiority cluster-randomised trial, in the Jewish population showed that DVD-195 
based pre-test counselling for population BRCA-testing is an effective, acceptable, non-inferior, time-196 
saving and cost-efficient alternative to traditional genetic-counselling.[15] Other studies in high-risk 197 
women have established telephone-counselling is an effective non-inferior alternative to traditional 198 
genetic-counselling.[13] The Israeli and Canadian population-based studies successfully undertook 199 
BRCA-testing without pre-test counselling, and provided post-test counselling. Around 50% of 200 
BRCA-carriers and 20% of overall participants in the Canadian population-based study expressed a 201 
preference for pre-test counselling after receiving their results.[53] Nevertheless, high satisfaction 202 
rates (91-95%) are reported in all (UK/Israeli/Canadian) population-based BRCA-testing studies. A 203 
recent UK pilot study has shown acceptability of a web decision-aid plus helpline and post-test 204 
counselling approach for population-based testing.[56] Robust RCT data comparing pre-test 205 
counselling with decision-aid and helpline or post-test only counselling alone are lacking. 206 
An initial paper confirms the cost-utility of population testing compared to no testing.[44] Three 207 
published analyses have evaluated cost-effectiveness of population-based BRCA-testing compared to 208 
current standard of clinical-criteria/FH testing in: the AJ population,[57] the AJ-population with 209 
varying AJ-ancestry[58] and the Sephardi-Jewish population.[59] These show that BRCA-testing in 210 
the Jewish-population is extremely cost-effective compared to FH-based testing. In fact in most 211 
published scenarios the intervention is cost-saving for both UK and USA health systems,[58] saving 212 
both lives and monies. Overall data thus strongly support the introduction of population-based 213 
BRCA-testing in the Jewish population. It is time guidelines change to reflect this.  214 
The challenge of implementation: There is no single best/ideal model for implementing 215 
population-based BRCA-testing in the Jewish community. It is likely that different/bespoke models 216 
will be needed for various health systems and contexts. Implementation will need development of 217 
testing pathways through a community or primary care based approach outside the traditional 218 
hospital based genetics clinic model, particularly in regions with large or dense Jewish populations. 219 
Areas with small or sparse populations could even be absorbed within the current clinical genetics 220 
system through changes in testing criteria. Implementation will require significant efforts towards 221 
engagement of community leaders, charities, stakeholders, opinion makers and Rabbis across all 222 
sections of the community. Additionally downstream pathways for management of unaffected 223 
carriers (including genetics services, gynaecologists, breast clinicians and screening and prevention 224 
services) will need expanding or establishing. This will need integration into GP networks to ensure 225 
adequate infrastructure and coherent pathways for managing newly identified mutation carriers. 226 
This needs to be coupled with information campaigns to increase both public and health professional 227 
awareness.  228 
 229 
3.2. Other founder populations 230 
Specific BRCA founder mutations have been described in a number of other founder populations 231 
(in addition to the Jewish population). These include Polish, French, Swedish, Norwegian, Dutch, 232 
Hispanic, Malaysian, Afro-American, Pakistani, Filipino, Inuit and Bahamian populations.[60-62] 233 
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 Findings of BRCA founder mutation testing studies from the Jewish population could also have 234 
implications for BRCA-testing in other founder populations. However, it is difficult to currently 235 
generalise these beyond this to the rest of the non-founder general population. The Polish ‘Twoj Styl’ 236 
study offered Polish BRCA1 founder mutation testing to 5024 women through a magazine 237 
advertisement.[63] Post-test counselling was provided to mutation carriers identified and high 238 
satisfaction rates (97%) reported overall. However, this was not true unselected population testing as 239 
there was ascertainment bias with testing offered only to women with cancer or a FH of 240 
breast/ovarian cancer.  241 
3.2. General Population and Panel Testing  242 
Next generation sequencing has enabled testing of multiple CSGs at the same time, i.e. Panel 243 
testing. This is now being implemented in clinical genetics for women at increased risk fulfilling usual 244 
clinical-criteria. Population-based testing too can incorporate multiple genes on a NGS panel. The 245 
panel of genes needs to have established analytic validity (sensitivity, specificity, reliability, and 246 
assay robustness- to reliably and accurately measure the genotype) and clinical validity (test’s ability 247 
to reliably and accurately predict the associated disorder/ phenotype).[64] A key unassailable 248 
principle underpinning extending panel testing to a population-based setting is only testing for those 249 
genes which have well-established ‘clinical utility’ i.e. demonstrable clear net clinical benefit 250 
(clinically effective) which can impact disease outcome.[64] A number of genes widely available or 251 
offered through panels by gene testing companies/laboratories do not yet have well-established 252 
clinical utility. However, the list of genes with proven clinical utility will evolve and expand in the 253 
coming years. 254 
A number of other moderate/high penetrance CSGs (in addition to BRCA1/BRCA2) can be 255 
incorporated into a population testing panel. Amongst the BC genes, PALB2 confers non-syndromic 256 
quasi-Mendelian susceptibility to BC (BC-risk till age 80 years =44%)[65] for which equivalent 257 
interventions of MRI screening / preventive mastectomy are now offered to mutations carriers, and 258 
hence, PALB2 can be incorporated. Although ATM and CHEK2 are offered on some commercial 259 
panels, clinical testing of these genes is not currently routinely undertaken in most centres as the risks 260 
conferred by mutations in these genes are moderate (RR~1.5-2) and MRI/mastectomy not routinely 261 
offered for this. Hence, these are probably currently best left out of a population testing panel. 262 
Amongst the newer moderate risk OC genes, risk estimates for RAD51C, RAD51D and BRIP1 (OC-263 
risks ~6-11%) have been recently validated. We showed that surgical prevention (RRSO) is cost-264 
effective at ≥4-5% OC-risk.[66,67] This enables clinical-utility for clinical-testing for these newer 265 
moderate OC-risk genes and the option of surgical prevention in unaffected women. Testing for these 266 
genes is now incorporated into clinical practice[68] and can be included in a population-based panel. 267 
Additionally Lynch-Syndrome (LS) MLH1/MSH2/MSH6 mismatch-repair (MMR) genes have a 40-268 
60% risk of colorectal-cancer, 30-45% risk of EC and 6-14% risk of OC.[69] LS/MMR-carriers can 269 
benefit from 1-2 yearly colonoscopies for colorectal-cancer screening and opt for daily aspirin[70] or 270 
prophylactic hysterectomy-&-oophorectomy for cancer prevention.[71] Amsterdam-II or Bethesda 271 
criteria used to identify MLH1/MHS2/MSH6 carriers in clinical practice miss 55-70% or 12-30% 272 
(respectively) of these MLH1/MHS2/MSH6 carriers[72] even amongst those with cancer. Thus, 273 
MLH1/MHS2/MSH6 are also potential candidate CSGs that can be included in an extended 274 
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 population germline testing panel. Overall these mutations account for around 15%-20% OC,[73] 6% 275 
BC,[74] 4-6% EC[75] and 4% bowel-cancers.[76]  276 
Initial survey based data suggest that population-testing for OC gene mutations for risk 277 
stratification may be acceptable to 75% women[39] and 72% women anticipate they would engage in 278 
positive health behaviour changes in response to BC/ OC risk disclosure following genetic testing.[40] 279 
An ongoing UK pilot study (ISRCTN54246466) shows feasibility of counselling and recruitment for 280 
panel genetic-testing for multiple moderate-high penetrance OC genes in unselected general-281 
population women ascertained through primary care.[56] The team in Toronto have implemented 282 
unselected BRCA testing for general population Canadian women and men over 18 years who are 283 
willing to pay for this themselves, through a Direct to Consumer testing model within ‘The Screen 284 
Project’ (http://www.thescreenproject.ca/) study. We recently evaluated the cost-effectiveness of 285 
population-based panel testing for OC and BC gene mutations 286 
(BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) by comparing this strategy to the usual clinical-287 
criteria/FH based testing for both UK and US health systems.[37] Modelling showed that population-288 
based panel testing for BC/OC CSGs was more cost-effective than any currently used clinical-289 
criteria/FH-based strategy: either clinical-criteria/FH-based BRCA-testing or clinical-criteria/FH-290 
based panel testing. The ICER (incremental cost-effectiveness ratio) were well below the UK 291 
£30,000/QALY (ICER= £21,599.96/QALY) and USA $100,000/QALY (ICER=$54,769.78/QALY) 292 
thresholds in the UK and USA respectively. Sensitivity analyses demonstrated that population-293 
testing was the cost-effective and the preferred strategy in 84% UK and 93% USA simulations 294 
respectively. This could potentially prevent thousands more BC and OC cases over and above current 295 
policy. This was estimated to be 17505 OC and 64493 BC cases prevented in UK women, and 65221 296 
OC and 237610 BC cases prevented in US women.  297 
However, cost-effectiveness modelling, like all such analyses incurs assumptions, and further 298 
research is necessary for prospective validation of some key assumptions. Jewish data cannot be 299 
directly extrapolated or generalised to the non-Jewish general-population and general population 300 
implementation studies are necessary to evaluate the impact and reconfirm cost-effectiveness of 301 
population-based panel testing. More data are needed on uptake rates of screening and prevention 302 
options in mutation carriers without a strong FH of cancer. A critical issue which needs addressing 303 
is the management of variants of uncertain significance (VUS). Further research is needed around 304 
giving VUS results back to individuals, their ability to deal with uncertainty, the impact of this result, 305 
developing a robust platform for VUS monitoring and evolving an acceptable long-term management 306 
pathway for this. 307 
3.3. Return of ‘incidental’ or ‘secondary’ findings of cancer gene mutations in population research 308 
studies  309 
Some studies have offered return of incidental or secondary findings of post hoc genetic testing 310 
undertaken in patients recruited for other research purposes. Thompson et al undertook post-hoc 311 
genetic testing for BRCA mutations in 1997 women and Rowley et al reported testing in 5908 women 312 
over 40 years (mean age 59.2 years) undergoing mammographic screening for BC in the Australian 313 
Life-pool study.[77,78] Secondary findings of BRCA testing in 50,726 men and women have also been 314 
reported through the MyCode Community Health Initiative.[79,80] Preliminary outcomes from such 315 
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 studies show acceptability of returning clinically relevant genetic research results or secondary 316 
findings along-with engagement with screening/preventive services and are supportive of the 317 
concept of broadening access towards a population based approach. These studies give a good idea 318 
of mutation rates. In the 100,000 Genomes Project ‘additional looked-for findings’ are being offered 319 
as part of the whole genome analysis (and include 10 cancer-susceptibility genes).[81] Additionally 320 
in many studies the sub-groups opting for return of incidental/secondary looked-for findings are 321 
highly selective and not generalizable to an unselected unaffected general-population. For e.g. the 322 
100,000 Genomes-Project is not a true population-cohort but comprises of individuals with cancer 323 
and families with rare paediatric diseases. However, this ‘bolt-on’ paradigm of returning additional 324 
secondary-findings is very different and not equivalent/identical to prospective uptake of testing 325 
CSGs in an unselected unaffected population. Data from these studies cannot be equated to outcomes 326 
of impact of true population-based testing. Such an approach does not address in an unbiased and 327 
prospective manner key questions of population testing around logistics; information giving, consent 328 
and true uptake; VUS management; and subsequent uptake of screening and prevention 329 
interventions. These outcomes could potentially be very different when apriori consent is sought for 330 
genetic testing for specific clinically actionable gene mutations, compared to vague/less-informed/un-331 
informed consent related to imprecisely defined secondary outcomes in post-hoc research studies. 332 
3.4. A potential strategy for chronic disease prevention  333 
According to the US Centres for Disease Control & Prevention (CDC), 50% US adults have ≥1 and 334 
25% US adults have ≥2 chronic health conditions and the latter accounts for >90% Medicare 335 
expenditure. CDC suggests that chronic diseases and injuries contributed to 2.7 million deaths in 336 
2015.[82] Corresponding treatment costs and resulting lost productivity amounted to $1.3 trillion. In 337 
England chronic conditions account for 50% of GP appointments, 64% outpatient appointments, 70% 338 
inpatient bed days, and 70% of the total health and care spend.[83]  The increasing prevalence of 339 
long-term/chronic conditions is the biggest challenge facing the UK National Health Service 340 
(NHS)[83] and many other health systems. Addressing this is critical to put health systems in a better 341 
position to remain viable for the future. The Milken Institute (a non-profit, nonpartisan economic 342 
think tank) have projected that by 2023 if we improved prevention, the US could avoid 40 million 343 
cases of chronic disease, cut treatment costs by $220 billion, and increase GDP by $900 billion.[84] 344 
According to the CDC commissioned National Vitals Statistics Reports the top five causes of deaths 345 
from chronic disease in 2015 were: 1) heart disease 2) cancer 3) lung disease 4) accidents 5) strokes.[82] 346 
Many of these can be prevented. WHO estimates that by 2030 the number of deaths due to heart 347 
disease, cancer, lung disease, accidents and strokes would rise by 24%, 37%, 32%, 14% and 29% in the 348 
Americas and by 23%, 45%, 41%, 23% and 28% worldwide respectively.[85] As validated disease 349 
specific models for risk prediction improve or develop and evolve, they can be used for population 350 
stratification to target the proportion of the population at highest risk of chronic disease. A prime 351 
example is cardiovascular disease. Testing for familial hypercholesterolemia could be added to any 352 
other genetic testing strategy. In addition going forward complex models incorporating 353 
epidemiological, lifestyle and single nucleotide polymorphism (SNP) data may reach broad mass 354 
based clinical applicability for population stratification and targeted primary prevention. A future 355 
population testing programme could target other diseases in addition to cancer. Implementing a new 356 
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 comprehensive population testing strategy can herald a paradigm change in approach which 357 
shifts/nudges the needle of healthcare towards prevention. 358 
 359 
Addressing the increasing burden of chronic disease poses a major challenge for the future. 360 
Different organizations at times give conflicting recommendations which in turn can be exacerbated 361 
by the advocacy positions of special interest groups, leading to uncertainty amongst clinicians and 362 
inconsistent implementation. Clinicians due to increasing time pressures and employers/payers 363 
struggling with accelerating health care costs may question the value of some preventive 364 
interventions. Insurance coverage for individual preventive services, especially new technologies, is 365 
inconsistent.[86,87] Public messages conveyed are often inconsistent and increasingly coloured by 366 
commercial self-interest. Racial and ethnic minorities, socio-economically deprived and other 367 
underserved populations have a higher burden of chronic disease and need special attention to reach 368 
their full health potential.[88] To this end, it is vital to also address social determinants of health, 369 
including economic, social, and geographic factors that influence the health of populations and 370 
contribute to chronic diseases and injury.  371 
 372 
3.5. Population Risk Stratification: beyond high penetrance genes 373 
Newer risk prediction models incorporating validated SNPs (as a polygenic risk score) and 374 
epidemiological/clinical factors have improved the precision on individualised risk prediction. This 375 
allows division of the population into risk strata, such that the highest risk strata have a significant 376 
higher risk relative to the lower strata, enabling a) targeted risk stratified screening and/or b) targeted 377 
prevention for the higher risk strata, as long as the risks of individuals in these strata lie above a well-378 
defined threshold of clinical utility (benefit and effectiveness). It may also identify a low-risk stratum 379 
who may benefit for less intense or no screening. This can be useful for making both individualised 380 
risk based decisions and population-based screening or prevention programmes. For example, 381 
models have been developed for breast, prostate and ovarian cancer. The Predicting the Risk of 382 
Cancer At Screening (PROCAS) study (UKCRN-ID 8080) showed that the addition of SNPs and 383 
mammographic breast density to the Tyrer-Cuzick model improves BC risk prediction and could be 384 
used for risk stratified screening in general-population women taking part in a national (NHS) Breast 385 
Screening Programme.[89] This was associated with lower- anxiety but slightly higher cancer worry 386 
than comparison women, with no consistent effect on intention to change behaviour, considerable 387 
variation in understanding of test results but high overall satisfaction.[90] The PROMISE Feasibility 388 
Study is evaluating the acceptability and feasibility of undertaking a study to stratify an unselected 389 
general population on the basis of their predicted lifetime OC-risk as well as offer risk management 390 
options of screening and prevention. The population is stratified into low (<5% OC-risk), intermediate 391 
(5-10% OC-risk) and high (>10% OC-risk) risk groups, using a model incorporating SNP based 392 
polygenic-risk score, BRCA1/BRCA2/RAD51C/RAD51D/BIP1 mutations and epidemiological data. 393 
Personalised SNP based profiles are also being used for melanoma risk stratification. The SOMBRA 394 
(Skin health Online for Melanoma: Better Risk Assessment) RCT, investigates personalised SNP 395 
testing for melanoma risk versus un-tested controls,[91] in terms of short-term sun protection/self-396 
examination, communication, beliefs, test comprehension/recall, satisfaction and cancer related 397 
distress following testing.[91] An Australian pilot RCT (ACTRN12615000356561), evaluated the 398 
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 feasibility and acceptability of communicating personalised SNP derived polygenic-risk scores for 399 
melanoma to the public, and its preliminary impact on health behaviour and psychosocial outcomes 400 
in 118 individuals.[92] Participants were randomised to intervention (personalised booklet & genetic 401 
counselling presenting melanoma polygenic risk) and control (non-personalised educational 402 
materials) arms.[92] Results showed no significant difference in behavioural effects, skin cancer 403 
related worry or psychological distress at 3 months.[92] A lot more research is needed to evaluate 404 
risk model based stratified screening and prevention, including implementation studies evaluating 405 
clinical effectiveness, impact, cost-effectiveness, health behaviour, psychology, ethical and social 406 
consequences.  407 
4. Conclusions 408 
Our healthcare structure is currently focused predominantly towards improving diagnosis & 409 
treatment of disease rather than illness prevention. The current clinical model for genetic testing is 410 
based on FH and serial referral through healthcare services.  It requires people to develop cancer 411 
before identifying unaffected individuals in the family to target prevention. This process is inefficient, 412 
resource intense and misses a large proportion of individuals/mutation carriers at risk. Population 413 
testing can overcome these limitations. The ability to test populations on a large scale is now 414 
available, testing costs are falling and the acceptability/awareness of testing is rising. Population-415 
based BRCA testing in the Jewish population has been extensively evaluated and found to be 416 
acceptable, feasible, clinically effective, safe, associated with high satisfaction rates and cost-effective. 417 
There are not many medical interventions that have the potential to save both lives and monies, but 418 
BRCA-testing in the Jewish population is one of them. Available data support change in guidelines 419 
to population based BRCA testing in the Jewish community.  420 
Ongoing studies are evaluating population based genetic testing for CSGs in the general 421 
population. Initial analysis suggest this approach is potentially cost-effective for a panel of BC and 422 
OC gene mutations. The increasing appreciation and recognition of complexities of tumour 423 
heterogeneity, tumour evolution and resistant mutations associated with metastatic disease has 424 
moderated the initial anticipated impact of precision oncology driven drug therapy based 425 
approaches. Population-testing for established cancer-genes can provide an impetus to increase 426 
carrier detection-rates to maximise prevention and reduce cancer burden. A cancer prevention 427 
population-based genetic testing programme can serve as an important model, with programme 428 
outputs subsequently informing potential applicability and development of programmes for other 429 
chronic diseases. 430 
While population testing holds great promise, several challenges need to be addressed along the 431 
way for this to materialise. To maximise the impact of population testing a future multi-gene and/or 432 
multi-disease panel testing approach/strategy needs to ensure: A) Clinical utility: Net clinical benefit 433 
on disease outcome taking into account benefits and harms of the intervention. B) Equal access: 434 
Ensuring equal access to disease prevention initiatives for all communities regardless of ethnicity, 435 
socio-economic background or gender, etc. C) Broadening research: For effective prevention and 436 
eradicating chronic disease it is critical to prioritise high quality research into disease prevention. 437 
There needs to be rebalancing of research funding from diagnosis/treatment towards prevention. For 438 
e.g., only 5% UK research funding goes into prevention.[93] The impact of panel germline population 439 
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 testing needs to be better understood and evaluated. D) Robust implementation pathways: these need 440 
to be context and health-system/population specific. E) Cost-effectiveness: Sustainable prevention 441 
strategies, need to be underpinned by evidence-based approaches that are economically viable and 442 
maximise the number of years lived in health. Policy makers and funders need to be educated about 443 
the significant cost savings that result from modest increases in prevention funding and potential 444 
savings & increased productivity that can result from employers/insurers/health funders promoting 445 
prevention. F) Consistent coherent messaging: Public messages need to be consistent, not be 446 
biased/swayed by commercial/vested interests, need to increase health professional and public 447 
awareness, and pay special attention to minority, socio-economically deprived and underserved 448 
populations or others with higher burden of disease. 449 
 450 
 451 
 452 
 453 
  454 
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